Latest news

• Sanofi and GSK report positive data for COVID-19 Beta vaccine

  Sanofi shared positive data earlier in June from two trials conducted with its new COVID-19 booster vaccine, which was modelled on the Beta variant antigen and utilised GSK’s pandemic ... He added: “With the immunogenicity data from our Beta-booster

• Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

  Sanofi and GSK have jointly developed a next-generation COVID-19 booster vaccine candidate, based on Sanofi’s recombinant Beta variant antigen and combined with GSK’s pandemic adjuvant. ... The independent COVIBOOST study showed that, following a

• Moderna announces trial results for new COVID-19 booster vaccine candidate

  Moderna has shared new clinical data evaluating its COVID-19 booster vaccine candidate, mRNA-1273.214 – containing mRNA-1273 (Spikevax) – and a vaccine candidate targeting the Omicron sub-variant. ... If approved, it could be used as a second booster

• AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

  AstraZeneca has received approval from the European Medicine Agency (EMA) for its COVID-19 vaccine, Vaxzevria, to be used as a third-dose booster to protect adults against the virus. ... Mene Pangalos, executive vice president, BioPharmaceuticals R&D,

• UK trial of fourth vaccine dose shows increased protection against COVID-19

  The results of the study showed the booster vaccine was particularly effective in those over 70. ... Commenting on the study findings, UK Health and Social Care Secretary Sajid Javid said this "further evidence underlines the importance of people coming